Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Analysis of Compositional Bias in a Commercial Phage Display Peptide Library by Next-Generation Sequencing

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers.

METHODS: We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression.

RESULTS: About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P < 0.001). The survival analysis included 584 patients. Positive ER status was protective in the first 5 years from diagnosis (multivariate HR = 0.49; 95% CI 0.26-0.93, P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07-3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26-4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11-3.59, P = 0.02).

CONCLUSIONS: The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones.

Original languageEnglish
JournalBritish Journal of Cancer
Volume123
Issue number11
Pages (from-to)1608-1615
Number of pages8
ISSN0007-0920
DOIs
Publication statusPublished - Nov 2020

ID: 61368879